Clinical Trial

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-03-25; most recent amendment 2026-07-07.
Status change: Active, Not Recruiting → Completed 2025-07-09
Trial Details
NCT Number NCT06905327
Lead Sponsor Novartis Pharmaceuticals
Conditions Mild Hypertension
Enrollment 56 participants
Start Date 2023-03-08
Primary Completion 2024-09-25 (estimated)
Study Completion 2025-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-09